No definition available.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
557745 |
1. Apply sex-specific ruleNone |
557745 |
2. Check conditionsNone |
557745 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters: 2 out of 7 registries used, show all original rules. |
385 |
4. Check minimum number of eventsNone |
385 |
5. Include endpoints |
484 |
6. Filter based on genotype QC (FinnGen only) |
425 |
Control definitions (FinnGen only)
- Control exclude
- L12_PAPULOSQUAMOUS
Extra metadata
- Level in the ICD hierarchy
- 3
- First used in FinnGen datafreeze
- DF2
- Parent code in ICD-10
- L40-L45
- Name in latin
- Aliae morbositates papulosquamosae
Similar endpoints
↥List of similar endpoints to
Other papulosquamous disorders
based on the number of shared cases.
Similar with more cases:
- Papulosquamous disorders
- Diseases of the skin and subcutaneous tissue
- Any event in hilmo or specialist outpatient
Similar with less cases:
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 3924 | 2160 | 1732 |
| Only index persons | 3067 | 1745 | 1322 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.06 | 0.06 | 0.05 |
| Only index persons | 0.06 | 0.06 | 0.05 |
| Median age at first event (years) | |||
| Whole population | 43.28 | 46.71 | 38.85 |
| Only index persons | 41.53 | 44.89 | 37.09 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 425 | 251 | 174 |
| Unadjusted period prevalence (%) | 0.09 | 0.09 | 0.08 |
| Median age at first event (years) | 51.38 | 47.35 | 57.19 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 450
- Matched controls
- 4500
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
D05BB02
ATC
acitretin; oral
73.9
126.6
69
11
L44.8
ICD-10 Finland
Other specified papulosquamous disorders
+∞
99.8
92
*
L44.0
ICD-10 Finland
Pityriasis rubra pilaris
+∞
95.3
88
*
D07AC01
ATC
betamethasone; topical
5.4
68.9
279
1047
TQX10
NOMESCO Finland
Biopsy of skin and subcutaneous tissue
7.4
68.3
118
207
L44.9
ICD-10 Finland
Papulosquamous disorder, unspecified
192.7
64.9
66
*
6970A
ICD-9 Finland
Lichen planus[LICHEN RUBER PLANUS]
+∞
56.5
53
*
L44.2
ICD-10 Finland
Lichen striatus
+∞
53.2
50
*
D07XC01
ATC
betamethasone; topical
5.8
51.4
113
247
D07AD01
ATC
clobetasol; topical
4.9
49.4
142
389
L30.9
ICD-10 Finland
Dermatitis, unspecified
4.4
48.5
175
571
L40.0
ICD-10 Finland
Psoriasis vulgaris
66.5
46.5
53
9
D05AX52
ATC
calcipotriol, combinations; topical
10.3
43.5
51
55
L44.1
ICD-10 Finland
Lichen nitidus
+∞
42.4
40
*
D07AC13
ATC
mometasone; topical
3.8
41.5
199
778
E0000UV, ,
ATC
3.7
40.2
274
1338
D05AX02
ATC
calcipotriol; topical
13.9
37.9
36
28
D07AB02
ATC
hydrocortisone butyrate; topical
3.2
30.6
193
863
L43.8
ICD-10 Finland
Other lichen planus
114.6
30.1
32
*
TQW80
NOMESCO Finland
Local dermatologic skincare
9.6
28.1
34
38
E000001, ,
ATC
3.3
27.0
134
515
L44.3
ICD-10 Finland
Lichen ruber moniliformis
+∞
23.1
22
*
L04AX03
ATC
methotrexate; systemic
3.9
21.1
69
200
D07AB08
ATC
desonide; topical
3.3
18.9
79
269
L40.5
ICD-10 Finland
Arthropathic psoriasis
+∞
18.9
18
*
E000003, ,
ATC
5.0
18.9
42
90
L43.9
ICD-10 Finland
Lichen planus, unspecified
30.2
17.6
23
8
D02AE01
ATC
carbamide; topical
4.1
16.9
49
130
E000002, ,
ATC
3.2
16.8
75
265
M07.3*L40.5
ICD-10 Finland
Other psoriatic arthropathies
88.2
15.7
17
*
R21
ICD-10 Finland
Rash and other nonspecific skin eruption
4.1
14.9
42
109
L26
ICD-10 Finland
Exfoliative dermatitis
154.8
14.5
15
*
D01AC20
ATC
imidazoles/triazoles in combination with corticosteroids; topical
2.3
13.2
124
634
D07AB01
ATC
clobetasone; topical
5.0
11.6
25
52
D07AA02
ATC
hydrocortisone; topical
2.4
11.6
87
401
69619
ICD-8 Finland
Psoriasis and similar disorders, Psoriasis alia sive NUD (vulgaris)
+∞
11.5
11
*
WXQ27
NOMESCO Finland
UVB narrow spectrum light therapy
16.0
10.9
17
11
H02AB06
ATC
prednisolone; systemic
2.0
10.9
225
1525
L40.9
ICD-10 Finland
Psoriasis, unspecified
28.8
10.8
14
5
S29
ICPC
Skin symptom/complaint other
2.2
10.4
111
591
M07.3
ICD-10 Finland
Other psoriatic arthropathies
102.1
9.4
10
*
R06AE07
ATC
cetirizine; oral
1.9
9.2
204
1392
134
Kela drug reimbursment
General erythroderma
37.5
9.1
11
*
D07BA04
ATC
hydrocortisone and antiseptics; topical
2.5
8.8
56
238
L40.3
ICD-10 Finland
Pustulosis palmaris et plantaris
14.4
8.7
14
10
L40.8
ICD-10 Finland
Other psoriasis
51.0
8.7
10
*
XQ848
NOMESCO Finland
Dermatological photography
4.3
8.6
22
53
M25.5
ICD-10 Finland
Pain in joint
1.9
8.5
161
1039
319
Kela drug reimbursment
Adalimumab, brodalumab, certolizumab pegol, etanercept, guselkumab, infliximab, ixekizumab, risankizumab, sekukinumab and ustekinumab (skin psoriasis)
+∞
8.4
8
*
D07BC01
ATC
betamethasone and antiseptics; topical
2.4
8.3
59
264
L40
ICD-10 Finland
Psoriasis
12.0
8.1
14
12
D07BB04
ATC
hydrocortisone butyrate and antiseptics; topical
2.2
8.0
69
336
S87
ICPC
Dermatitis/atopic eczema
4.5
7.8
19
44
WZB00
NOMESCO Finland
Telephone prescription or other care instructions
1.8
7.6
136
858
L04AX01
ATC
azathioprine; systemic
3.6
7.5
25
73
L43.0
ICD-10 Finland
Hypertrophic lichen planus
+∞
7.3
7
*
69698
ICD-8 Finland
Psoriasis and similar disorders, Other disorders
+∞
7.3
7
*
J01FF01
ATC
clindamycin; systemic
1.8
7.2
125
779
L43
ICD-10 Finland
Lichen planus
12.3
7.1
12
10
E000006, ,
ATC
2.8
7.1
36
136
L30.8
ICD-10 Finland
Other specified dermatitis
3.8
7.0
21
57
Z01.5
ICD-10 Finland
Diagnostic skin and sensitization tests
2.4
6.9
50
225
L20.0
ICD-10 Finland
Besnier prurigo
2.5
6.9
45
193
N05BB01
ATC
hydroxyzine; systemic
2.8
6.8
35
133
UJD10
NOMESCO Finland
Esophagoscopy, gastroscopy and duodenoscopy
1.8
6.8
135
875
L01BA01
ATC
methotrexate; systemic
4.0
6.8
19
49
A07AA02
ATC
nystatin; oral
2.9
6.7
31
111
S21
ICPC
Skin texture symptom/complaint
2.0
6.7
80
440
L30.3
ICD-10 Finland
Infective dermatitis
3.7
6.7
21
59
8090/3-C44.3
ICD-O-3
Basal cell carcinoma, NOS, of skin of other and unspecified parts of face
3.9
6.6
19
50
XQ800
NOMESCO Finland
Prick test
2.5
6.5
40
167
A46
ICD-10 Finland
Erysipelas
2.0
6.4
70
372
TNX10
NOMESCO Finland
Arthrocentesis, unspecified region, unspecified region
2.7
6.4
34
132
69699, ,
ICD-8 Finland
+∞
6.3
6
*
69700
ICD-8 Finland
Lichen, Planus
+∞
6.3
6
*
L44.4
ICD-10 Finland
Infantile papular acrodermatitis [Giannotti-Crosti]
+∞
6.3
6
*
R2130
NOMESCO Finland
Counselling and guidance which enhance independent living
2.3
6.3
47
215
D02AX
ATC
Other emollients and protectives
3.5
6.2
21
62
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
310
2239
2.24
13.85
13.9
9.2
4.35
4.06
e9/l
1.11
271
1940
152
903
2.03
10.72
3.2
2.7
6.16
5.76
e6/l
0.17
141
826
198
1302
1.93
10.32
4.2
3.4
15.42
110.92
e6/l
1.23
159
1004
246
1741
1.91
10.22
2.8
2.5
75.95
76.37
nmol/l
0.08
230
1581
234
1665
1.84
9.22
6.8
5.0
35.61
35.83
g/l
0.25
220
1572
171
1118
1.85
8.72
3.8
3.3
0.21
0.45
e6/l
1.69
131
818
67
311
2.36
8.66
2.9
2.7
66.02
67.10
g/l
0.62
60
289
109
615
2.02
8.63
3.4
2.4
2.29
2.32
g/l
0.20
103
568
42
162
2.76
7.95
1.6
1.9
2.71
9.24
iu/ml
—
8
41
114
672
1.93
7.89
3.5
2.4
12.10
13.16
umol/l
0.93
109
623
350
2905
1.92
7.63
10.8
7.9
79.84
79.81
u/l
0.00
341
2758
32
109
3.08
7.55
1.4
1.3
273.28
316.47
ug/g
0.49
18
60
158
1053
1.77
7.30
2.9
2.1
2.84
2.86
mg/l
0.03
139
900
74
393
2.06
6.82
2.7
2.2
311.76
372.46
nmol/l
1.81
68
375
184
1331
1.65
6.04
3.9
3.2
2.35
2.35
mmol/l
0.00
171
1210
265
2101
1.64
6.00
4.9
4.0
0.04
0.74
estimate
0.47
49
410
54
267
2.16
5.98
1.8
1.6
—
—
—
0
0
263
2087
1.63
5.88
4.9
4.0
0.00
3.72
estimate
0.50
52
437
34
138
2.58
5.85
3.9
2.4
0.64
0.88
g/l
0.24
28
123
108
683
1.76
5.80
3.3
3.0
0.91
0.95
e6/l
0.06
53
356
260
2065
1.61
5.73
4.9
3.9
0.00
0.00
estimate
-0.00
51
431
31
122
2.65
5.67
4.1
2.1
0.00
0.04
g/l
0.50
26
113
220
1683
1.60
5.64
2.3
2.1
97.00
96.07
pmol/l
0.09
119
885
144
994
1.66
5.60
1.6
1.3
3.08
1.91
u/ml
0.21
40
261
29
114
2.65
5.32
1.2
1.3
—
—
—
0
0
12
18
6.82
5.28
1.4
2.7
—
—
—
0
0
139
963
1.64
5.28
3.3
2.9
369.40
342.69
umol/l
1.86
123
850
32
135
2.48
5.10
1.5
1.6
1.22
1.18
g/l
0.45
32
129
31
129
2.51
5.09
1.6
1.5
0.22
0.24
g/l
0.67
31
124
29
119
2.54
4.90
3.4
2.1
0.00
0.00
g/l
-0.00
24
108
162
1190
1.56
4.73
2.7
2.1
163.60
202.03
u/l
0.60
155
1131
25
98
2.64
4.63
1.4
1.2
—
—
—
0
0
254
2065
1.53
4.63
7.1
6.4
11.30
11.44
umol/l
0.08
240
1965
342
2977
1.62
4.54
5.2
4.3
14.91
14.73
pmol/l
0.69
313
2717
241
1945
1.51
4.50
8.9
6.9
1.21
1.21
mmol/l
0.14
217
1693
31
139
2.32
4.36
3.3
2.1
10.20
10.36
g/l
0.08
26
125
301
2558
1.53
4.31
6.0
4.7
1052.40
1696.70
e6/l
—
5
47
95
631
1.64
4.17
3.6
3.2
2.54
2.54
e6/l
0.00
40
306
10
17
5.99
4.15
3.1
4.1
733.40
875.00
u/ml
—
10
17
327
2846
1.55
4.05
6.4
4.2
12.67
11.54
mm/h
0.77
307
2653
218
1754
1.47
3.95
9.6
6.2
1.21
1.21
mmol/l
0.15
207
1619
172
1322
1.49
3.92
4.2
3.4
7.01
7.61
mmol/l
0.99
154
1117
8
11
7.38
3.87
1.6
1.0
9.72
9.66
ug/l
—
8
11
268
2261
1.46
3.70
6.7
4.9
6.80
6.61
mmol/l
0.66
258
2122
58
348
1.77
3.68
11.6
7.5
1.13
1.29
mmol/l
0.90
58
341
218
1771
1.45
3.67
14.3
12.8
1.16
1.22
inr
1.29
173
1462
28
130
2.23
3.66
1.4
1.6
236.61
316.74
mu/l
1.95
28
118
25
112
2.30
3.55
1.8
1.5
10.61
9.21
u/l
0.12
15
84
11
26
4.31
3.53
1.4
1.0
—
—
—
0
0
160
1240
1.45
3.39
5.1
4.1
10.43
9.83
mg/mmol
0.07
112
763
95
666
1.54
3.28
3.5
3.3
0.81
0.82
mmol/l
0.45
88
635
26
124
2.16
3.21
1.8
1.6
—
—
—
0
0
49
292
1.76
3.20
4.5
3.7
148.99
75.99
ng/l
1.61
42
263
13
40
3.32
3.16
1.7
1.2
—
—
—
0
0
105
763
1.49
3.06
3.0
2.7
2.43
2.45
mmol/l
0.83
93
688
167
1326
1.41
3.04
3.5
3.3
31.49
31.47
u/l
0.00
159
1265
7
12
5.90
3.03
1.6
1.0
1927.29
1649.33
miu/ml
—
7
12
382
3514
1.58
3.01
6.6
5.3
1.91
1.93
mu/l
0.10
358
3249
150
1171
1.42
2.99
1.8
1.7
19.22
20.24
nmol/l
0.41
135
992
230
1932
1.39
2.99
4.1
3.1
109.51
108.05
ug/l
0.05
212
1815
403
3760
1.69
2.94
24.0
15.5
22.57
23.28
mg/l
0.18
346
3082
11
32
3.50
2.92
1.4
1.0
—
—
—
0
0
39
224
1.81
2.89
1.9
1.8
—
—
—
0
0
102
748
1.47
2.83
1.4
1.3
22.85
35.61
iu/ml
0.78
27
241
61
400
1.61
2.81
4.5
3.6
1.82
1.75
mmol/l
0.05
54
335
88
629
1.50
2.77
1.8
1.7
1165.66
1168.39
nmol/l
0.01
70
472
5
6
8.41
2.75
1.0
1.0
—
—
—
0
0
30
162
1.91
2.69
2.6
2.2
120.78
4411.25
u/l
—
9
61
26
134
2.00
2.66
2.3
2.7
98.46
93.14
%
0.75
26
129
106
799
1.43
2.53
1.7
1.7
449.22
35714728.50
pmol/l
0.99
90
672
18
82
2.24
2.51
1.4
1.4
—
—
—
0
0
23
116
2.04
2.50
2.2
2.8
—
—
—
0
0
44
274
1.67
2.49
1.2
1.3
121.37
145.71
u/ml
0.24
20
104
92
678
1.45
2.47
1.4
1.3
10.18
9.26
u/ml
0.04
36
264
32
182
1.82
2.47
1.3
1.5
28.90
25.50
iu/l
0.18
25
142
23
118
2.00
2.40
2.7
3.0
4.02
3.57
g/l
0.50
23
113
188
1575
1.33
2.31
4.8
3.9
0.07
0.02
estimate
0.29
46
363
24
127
1.94
2.30
1.3
1.2
—
2.70
—
0
5
20
99
2.07
2.29
1.2
1.2
—
47.74
—
0
14
151
1227
1.35
2.27
3.4
2.6
66.20
65.16
u/l
0.03
137
1153
15
66
2.32
2.27
1.6
4.9
—
4125.33
—
0
6
413
3921
1.65
2.25
17.8
11.5
27.74
25.13
u/l
2.02
405
3812
19
93
2.09
2.25
1.3
1.3
—
—
—
0
0
10
35
2.90
2.22
1.2
1.2
—
—
—
0
0
10
35
2.90
2.22
1.2
1.2
—
—
—
0
0
56
384
1.52
2.15
2.8
2.5
50.35
31.04
u/l
0.54
46
323
10
37
2.74
2.08
1.2
1.2
—
—
—
0
0
10
37
2.74
2.08
1.2
1.2
—
—
—
0
0
415
3956
1.63
2.08
29.5
19.8
78.64
75.99
umol/l
0.57
409
3911
(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
21
111
1.94
2.04
1.9
2.4
0.39
0.37
iu/ml
—
8
63
272
2427
1.31
2.02
3.4
3.3
—
—
—
0
0
22
119
1.89
2.01
1.3
1.3
—
2.33
—
0
13
17
84
2.06
1.98
1.2
1.3
—
—
—
0
0
63
452
1.46
1.95
2.0
1.9
—
—
—
0
0
55
384
1.49
1.95
3.8
3.2
—
—
—
0
0
30
476
0.60
1.94
5.9
4.9
32.58
32.19
%
0.08
24
313
141
1157
1.32
1.94
5.3
4.1
0.00
0.00
estimate
0.50
46
407
66
480
1.44
1.91
2.1
1.8
—
—
—
0
0
378
3550
1.40
1.90
22.9
14.9
83.55
82.09
ml/min/173m2
0.59
350
3253
382
3595
1.41
1.88
5.6
5.0
6.12
5.90
mmol/l
1.82
357
3313
7
23
3.07
1.80
1.3
1.4
—
—
—
0
0
116
935
1.32
1.80
5.4
4.0
1.02
1.02
kg/l
0.04
72
623
22
124
1.81
1.79
1.2
1.3
—
—
—
0
0
18
95
1.93
1.78
3.3
2.9
0.89
2.10
index
—
9
58
94
736
1.35
1.77
4.5
4.0
224.33
315.44
ng/l
0.25
76
557
17
88
1.97
1.77
1.4
1.2
366.10
245.91
u/ml
—
10
43
62
453
1.43
1.76
2.3
3.1
5.17
7.55
umol/l
2.20
55
399
9
36
2.53
1.75
2.7
1.7
6.81
4.09
mg/l
—
9
36
113
912
1.32
1.73
3.0
2.4
—
—
—
0
0
37
244
1.56
1.72
1.2
1.3
—
39.53
—
0
18
59
430
1.43
1.70
10.8
7.6
0.38
1.07
mmol/l
0.54
47
361
400
3812
1.44
1.67
26.0
18.0
139.45
139.71
mmol/l
1.08
390
3741
10
41
2.47
1.65
1.2
1.1
—
—
—
0
0
10
41
2.47
1.65
1.2
1.1
—
—
—
0
0
15
77
1.98
1.61
1.5
1.4
—
—
—
0
0
15
77
1.98
1.61
1.5
1.4
—
—
—
0
0
400
3818
1.43
1.59
26.3
18.2
3.97
3.97
mmol/l
0.28
390
3742
10
44
2.30
1.56
1.2
1.1
—
—
—
0
0
19
108
1.79
1.53
1.1
1.1
—
—
—
0
0
136
1146
1.27
1.49
3.5
3.4
0.00
0.08
estimate
0.60
45
349
82
646
1.33
1.49
2.4
2.0
—
—
—
0
0
10
45
2.25
1.47
3.0
3.5
—
—
—
0
0
10
45
2.25
1.47
1.2
1.2
—
—
—
0
0
11
52
2.14
1.45
3.1
11.3
5.51
6.77
mmol/l
1.72
11
43
13
66
2.00
1.45
1.4
1.2
63.88
17.84
u/l
0.43
13
56
27
173
1.60
1.43
3.7
3.5
25.11
24.96
mmol/l
0.08
27
167
15
81
1.88
1.41
1.3
1.4
—
—
—
0
0
21
127
1.69
1.39
1.4
1.2
—
—
—
0
0
14
75
1.89
1.36
1.2
1.3
—
—
—
0
0
366
3470
1.29
1.33
7.9
6.2
40.30
39.01
mmol/mol
1.51
345
3271
6
24
2.52
1.31
1.0
1.0
—
—
—
0
0
16
91
1.79
1.30
1.3
1.5
3391.71
12571.29
e6/l
—
7
65
66
515
1.33
1.29
2.2
2.3
—
—
—
0
0
36
256
1.44
1.22
2.6
3.0
87.84
211.95
ng/l
3.17
31
233
200
1790
1.21
1.22
3.0
2.8
—
—
estimate
—
0
0
18
109
1.68
1.20
1.1
1.1
—
—
—
0
0
11
58
1.92
1.13
1.3
1.4
—
—
—
0
0
380
3640
1.28
1.12
6.1
5.0
4.50
4.61
mmol/l
1.24
359
3394
61
482
1.31
1.11
2.0
2.2
—
—
—
0
0
7
33
2.14
1.06
1.0
1.0
—
—
—
0
0
132
1150
1.21
1.04
3.0
3.3
1184.02
1309.46
ng/l
0.18
118
988
33
239
1.41
1.04
3.4
3.1
129.15
129.82
g/l
0.06
33
233
5
22
2.29
1.03
1.0
1.2
201.80
107.66
iu/ml
—
5
22
7
34
2.08
1.03
2.6
1.4
—
—
—
0
0
9
47
1.93
1.02
1.1
1.0
—
—
—
0
0
14
83
1.71
1.02
1.9
2.4
100.04
110.23
ug/min
—
8
43
96
813
1.23
1.00
1.7
1.7
—
—
—
0
0
176
1581
1.19
0.99
2.3
1.9
1.42
1.34
mmol/l
0.72
153
1337
5
23
2.19
0.98
1.4
1.3
—
—
—
0
0
17
108
1.60
0.98
5.4
3.4
19.10
2.19
ratio
—
9
61
278
2598
1.18
0.97
3.8
3.3
57.32
44.67
u/l
1.61
263
2453
24
166
1.47
0.96
1.3
1.2
0.14
3.39
u/ml
—
5
8
18
117
1.56
0.95
1.7
1.4
—
—
—
0
0
16
101
1.61
0.95
1.7
1.8
3.79
4.02
iu/l
—
7
42
419
4085
1.37
0.93
35.2
23.3
253.43
250.42
e9/l
0.41
407
4013
419
4085
1.37
0.93
35.2
23.2
91.22
90.91
fl
0.69
412
4048
419
4087
1.37
0.90
35.2
23.2
4.48
4.48
e12/l
0.08
407
4003
419
4087
1.37
0.90
36.6
23.7
40.10
40.31
%
0.35
412
4047
8
42
1.92
0.89
1.1
1.1
—
—
—
0
0
16
103
1.57
0.88
1.3
1.7
—
—
—
0
0
419
4090
1.35
0.87
35.6
23.4
134.05
134.65
g/l
0.36
413
4049
164
1482
1.17
0.84
4.1
3.9
37.73
76.79
ng/l
0.50
107
1058
10
163
0.60
0.80
2.5
2.1
2.08
4.06
mg/l
—
5
122
28
208
1.37
0.79
5.5
2.7
0.61
0.61
%
0.00
28
208
15
98
1.55
0.79
1.9
1.7
—
—
—
0
0
31
235
1.34
0.78
4.9
3.6
1.27
1.86
mmol/l
0.37
22
177
39
308
1.29
0.75
3.3
2.5
72.95
67.78
ml/min/173m2
0.33
21
129
21
150
1.42
0.75
1.7
1.6
11.50
9.55
u/ml
—
7
31
358
3451
1.18
0.73
5.1
4.2
1.35
1.26
mmol/l
1.65
334
3172
7
40
1.76
0.71
1.3
1.2
—
—
—
0
0
(3016894) Varicella zoster virus DNA [Presence] in Cerebral spinal fluid by NAA with probe detection
5
26
1.93
0.71
1.0
1.2
—
—
—
0
0
5
26
1.93
0.71
1.8
1.4
—
—
—
0
0
5
26
1.93
0.71
1.8
1.4
—
—
—
0
0
10
61
1.65
0.69
1.2
1.3
—
—
—
0
0
374
3625
1.19
0.67
5.6
4.9
1.39
1.48
mmol/l
3.71
351
3360
5
28
1.79
0.66
1.2
1.5
—
—
—
0
0
7
44
1.60
0.65
1.0
1.4
—
—
—
0
0
28
216
1.32
0.65
1.1
1.3
—
—
—
0
0
8
51
1.58
0.60
1.0
1.4
—
—
—
0
0
8
51
1.58
0.60
1.4
1.2
87.62
282.48
pmol/l
—
8
46
0
23
0.00
0.58
0.0
1.7
—
—
—
0
0
0
23
0.00
0.58
0.0
1.3
—
11.00
—
0
23
99
888
1.15
0.56
2.0
1.8
1.43
1.26
mg/l
0.29
78
693
34
277
1.25
0.54
5.8
3.4
5.21
5.12
kpa
0.35
34
270
6
39
1.55
0.53
1.3
1.1
—
—
—
0
0
379
3696
1.16
0.53
6.9
5.7
2.63
2.69
mmol/l
0.75
358
3440
10
66
1.53
0.53
1.2
1.2
13.00
1.86
u/ml
—
5
21
24
303
0.78
0.53
1.5
1.8
3.58
3.47
mmol/l
0.16
13
229
9
64
1.41
0.51
1.2
1.1
—
—
—
0
0
33
399
0.81
0.51
1.8
2.0
3.40
3.37
ratio
0.05
23
327
24
192
1.26
0.46
1.8
1.5
0.31
0.27
mg/l
0.11
12
87
10
70
1.44
0.42
7.1
3.8
9.55
8.64
pmol/l
—
10
70
97
887
1.12
0.42
4.8
4.6
21.97
22.03
%
0.01
44
433
120
1111
1.11
0.41
5.3
5.5
3.72
2.82
ug/l
0.30
110
984
0
15
0.00
0.41
0.0
1.1
—
—
—
0
0
5
76
0.65
0.36
1.2
1.4
—
—
—
0
0
36
311
1.17
0.35
1.6
1.4
—
—
—
0
0
25
210
1.20
0.33
1.4
1.4
—
—
—
0
0
6
47
1.28
0.32
2.5
2.7
104.33
106.28
mmol/l
—
6
47
38
429
0.88
0.30
6.4
6.7
—
—
—
0
0
25
213
1.18
0.29
4.7
2.8
18.66
44.97
u/ml
1.39
25
203
10
127
0.78
0.26
1.0
1.1
1.53
1.58
g/l
—
10
127
9
72
1.26
0.26
1.0
1.7
—
—
—
0
0
30
264
1.15
0.25
1.7
1.9
—
—
—
0
0
59
636
0.92
0.22
1.8
1.5
—
—
—
0
0
0
11
0.00
0.21
0.0
1.4
—
—
—
0
0
0
11
0.00
0.21
0.0
1.1
—
—
—
0
0
0
10
0.00
0.21
0.0
1.1
—
—
—
0
0
0
12
0.00
0.21
0.0
1.2
—
—
—
0
0
0
12
0.00
0.21
0.0
1.3
—
—
—
0
0
11
134
0.82
0.21
1.5
1.4
—
—
—
0
0
0
13
0.00
0.21
0.0
1.2
—
—
—
0
0
0
14
0.00
0.20
0.0
1.2
—
336.00
—
0
8
6
52
1.16
0.19
1.2
1.4
0.53
0.57
nmol/l
—
6
46
6
53
1.13
0.18
1.8
1.5
—
—
—
0
0
12
100
1.21
0.18
3.7
2.5
136.92
130.21
g/l
0.43
12
82
13
110
1.19
0.17
1.2
1.5
—
—
—
0
0
15
129
1.17
0.17
1.9
1.6
—
—
—
0
0
71
673
1.07
0.16
3.7
3.3
0.66
0.78
ug/l
0.72
52
443
6
78
0.77
0.15
1.3
1.5
—
—
—
0
0
6
78
0.77
0.15
1.0
1.6
—
—
—
0
0
8
97
0.82
0.14
1.4
1.7
—
—
—
0
0
10
115
0.87
0.10
1.2
1.7
—
—
—
0
0
5
47
1.06
0.09
2.8
2.7
1.18
1.19
mmol/l
—
5
47
6
54
1.11
0.09
1.8
1.5
—
—
—
0
0
6
55
1.09
0.09
1.8
1.5
—
—
—
0
0
6
55
1.09
0.09
1.8
1.5
—
—
—
0
0
6
55
1.09
0.09
1.8
1.5
—
—
—
0
0
6
55
1.09
0.09
1.8
1.5
—
—
—
0
0
8
91
0.88
0.07
1.3
1.4
—
—
—
0
0
15
139
1.08
0.05
3.1
1.7
—
—
—
0
0
41
396
1.04
0.05
3.8
4.3
14.73
19.12
ug/l
0.13
35
329
12
130
0.92
0.04
1.0
1.1
0.91
0.88
g/l
0.13
12
130
13
140
0.93
0.04
1.6
1.8
—
—
—
0
0
16
151
1.06
0.03
5.1
4.1
24.31
24.88
mmol/l
0.39
16
142
31
320
0.97
0.03
2.1
2.0
—
—
—
0
0
10
108
0.92
0.03
1.9
1.7
63.86
58.07
ug/l
—
10
96
11
103
1.07
0.02
1.4
1.4
92.64
226.66
pmol/l
0.61
11
98
10
94
1.07
0.01
1.7
1.6
—
—
—
0
0
15
144
1.04
0.00
3.4
2.0
—
—
—
0
0
21
214
0.98
0.00
1.0
1.1
—
—
—
0
0
14
143
0.98
0.00
1.1
1.4
118.17
260.24
miu/ml
—
6
69
0
8
0.00
-0.00
0.0
1.1
—
0.02
—
0
8
0
5
0.00
-0.00
0.0
3.8
—
2.60
—
0
5
0
5
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.7
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.0
—
—
—
0
0
6
60
1.00
-0.00
1.5
1.5
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.3
—
46.71
—
0
7
6
65
0.92
-0.00
1.3
1.5
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint L12_PAPULOSQUAOTH and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| L12_PAPULOSQUAOTH | 1.183 [0.96, 1.46] | 0.119 |
| Birth year | 0.99 [0.98, 1.0] | 0.027 |
During the follow-up period (1.1.1998 — 31.12.2019), 164 out of 1235 females with L12_PAPULOSQUAOTH died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| L12_PAPULOSQUAOTH | 1.496 [1.14, 1.97] | 0.004 |
| Birth year | 0.984 [0.97, 0.99] | 0.001 |
During the follow-up period (1.1.1998 — 31.12.2019), 184 out of 1017 males with L12_PAPULOSQUAOTH died.
Mortality risk
Mortality risk for people of age
years, who have L12_PAPULOSQUAOTH.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.083% | 0.332% |
| 5 | 0.566% | 1.753% |
| 10 | 1.522% | 4.204% |
| 15 | 2.952% | 7.479% |
| 20 | 5.118% | 12.236% |
Relationships between endpoints
↥Index endpoint: L12_PAPULOSQUAOTH – Other papulosquamous disorders
GWS hits: 1
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data